Web Results
Find Health Information on Healthline
Find Info About:
Healthline is the leading provider of health information.

law.justia.com/cases/federal/appellate-courts/ca1/11-1904/11-1904-2013-04-03.html

Kaiser Foundation Health Plan and Kaiser Foundation Hospitals (together, Kaiser), Aetna, Inc. and Guardian Life Insurance Company (Guardian) filed a coordinated complaint against Pfizer, Inc. and Warner-Lambert Company ( together, Pfizer). The coordinated plaintiffs asserted violations of, inter alia, the Racketeer ...

law.justia.com/cases/federal/district-courts/FSupp/922/1261/1592845

922 F. Supp. 1261 (1996). Arthur Ray BOWLING, et al., Plaintiffs, v. PFIZER, INC., et al., Defendants. No. C-1-91-256. United States District Court, S.D. Ohio, Western Division. March 1, 1996. *1262 Stanley Morris Chesley, Waite, Schneider, Bayless & Chesley Co. 1, Cincinnati, OH, for Arthur Ray Bowling, Julie Whyle, Janet ...

securities.stanford.edu/filings-documents/1044/PFE00_01/2010126_r01c_10CV03864.pdf

Dec 6, 2010 ... x. MARY K. JONES, Individually and on Behalf : Civil Action No. 1: 1 0-cv-03 864- AKH of All Others Similarly Situated,. : : CLASS ACTION. Plaintiff. : : CONSOLIDATED CLASS ACTION vs. : COMPLAINT FOR VIOLATIONS OF THE. : FEDERAL SECURITIES LAWS. PFIZER INC., HENRY A. McKINNELL,.

www.ncbi.nlm.nih.gov/pmc/articles/PMC4464844

Mar 14, 2011 ... The relative preference for R- versus S-HNE as initial substrates could play an important role in the removal of these electrophiles, as both enantiomers are reactive toward cellular nucleophiles and are presumed to be toxic (West et al., 2004). Although LPO generates both enantiomers of HNE, the unique ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC5656820

Sep 6, 2017 ... Bing et al reported 2 polymorphisms that were suggested to be associated with a higher risk of HZ in tofacitinib‐treated patients, although these polymorphisms ... This study was sponsored by Pfizer Inc. The manuscript was drafted, under direction from the authors, by Alice MacLachlan at Complete Medical ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC4035768

May 7, 2014 ... Biologics such as rituximab are an important component of oncology treatment strategies, although access to such therapies is challenging in countries with limited resources. This study examined access to rituximab and identified potential barriers to its use in the United States, Mexico, Turkey, Russia, and ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC2965864

Aug 17, 2010 ... Paired observations of pharmacokinetic parameter values of sunitinib and irinotecan alone vs the combination did not reveal significant drug–drug .... Response Evaluation Criteria for Solid Tumors version 1.0 (Therasse et al 2000) was used, requiring repeat imaging studies ⩾4 weeks after the initial ...

acrabstracts.org/abstract/efficacy-and-safety-of-intra-articular-sprifermin-in-symptomatic-radiographic-knee-osteoarthritis-results-of-the-2-year-primary-analysis-from-a-5-year-randomised-placebo-controlled-phase-ii-study

Oct 19, 2017 ... Marc C. Hochberg1, Ali Guermazi2, Hans Guehring3, Aida Aydemir4, Stephen Wax5, Patricia Fleuranceau-Morel4, Asger Reinstrup Bihlet6, Inger Byrjalsen6, ... Disclosure: M. C. Hochberg, Bioiberica SA, Bristol Myers Squibb, EMD Serono, Galapagos, IBSA SA, Eli Lilly, Novartis Pharma AG, Pfizer Inc., ...

journals.sagepub.com/doi/pdf/10.1350/clwr.2009.38.4.390

Abdullahi v Pfizer Inc 77 F. App'x 48 (2nd Cir, 2003). 228, 235. Abidin Daver, The [1984] AC ... Amin Rasheed Shipping Corp v Kuwait Insurance Co [1984] AC 50, HL. 213. Anderson v Eric Anderson Radio .... Friedman v NBC Inc. et al., 178 AD 2d 774, 577 NYS 2d 517, 26 December. 1991. 154–5. Fuji Finance Inc v Aetna ...